Answers are grounded in this paper and cite their sources.
Organoids are three-dimensional (3D) tissue-engineered models that recapitulate the structural and functional characteristics of native tissues in vivo . Recent advances in patient-derived organoid (PDO) culture technologies enable clinicians to predict treatment responses in vitro , potentially reducing therapeutic failure risks and mitigating patient morbidity. However, cancer exhibits profound inter- and intratumoral heterogeneity and genomic instability, influenced by variations in source tissues across tumor types and stages, as well as divergent culture conditions. Consequently, beyond technical quality, safety, and source tissue viability for PDO generation, critical determinants of assessment efficacy include the clinical characteristics of patient cohort and the pharmacological profiles of tested agents. To synthesize current methodologies, evaluate challenges, and promote better application of PDO-based drug screening in clinical and preclinical oncology, this study comprehensively evaluates reported PDO drug sensitivity assays, emphasizing their clinical relevance and capacity to model neoplastic heterogeneity. Specifically, the impact of tumor type, disease stage, guideline-recommended chemotherapeutics, and frequently targeted pathways across diverse solid tumors has been analyzed. Building on these findings, this review explores future directions for organoid-based drug testing, highlighting two transformative innovations: PDO co-culture systems that reconstitute the tumor microenvironment (TME), and artificial intelligence (AI)-driven evaluation algorithms designed to enhance preclinical screening accuracy and ultimately improve patient outcomes through advanced in vitro modeling.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: